KemPharm, Inc. Expands Pain Therapy Pipeline With Discovery of KP511
Published: Oct 26, 2011
NORTH LIBERTY, Iowa, Oct. 26, 2011 (GLOBE NEWSWIRE) -- KemPharm, Inc. today announced it plans to initiate development of its recently identified lead compound KP511, a first-in-class oral prodrug of hydromorphone, which is a commonly used medication for the management of pain in patients where an opioid analgesic is appropriate. KP511 was identified using the Company's Ligand Activated Therapy (LAT) approach. KP511 is the second product candidate in KemPharm's pain therapy portfolio, which also includes KP201, a prodrug of hydrocodone that is on track for an NDA filing in early 2013.